According to research reviewed by Gram, vitamin D3 supplements reduced disease activity in people with clinically isolated syndrome and early multiple sclerosis in the D-Lay MS clinical trial, with no serious side effects reported. While vitamin D deficiency is a known MS risk factor, this evidence suggests supplementation may be most effective when started early, before MS fully develops, potentially working alongside other MS medications.
Researchers are exploring whether vitamin D supplements might help people in the early stages of multiple sclerosis (MS), before the disease fully develops. A clinical trial called D-Lay MS found that vitamin D3 supplements reduced disease activity in people with clinically isolated syndrome (CIS)—an early warning sign of MS—and in early-stage MS patients, without causing serious side effects. While vitamin D deficiency is known to increase MS risk, this research suggests supplements might offer additional protection when combined with other MS treatments. However, scientists want more studies to confirm these findings and understand how long-term vitamin D use affects disease progression.
Key Statistics
The D-Lay MS clinical trial found that vitamin D3 supplementation reduced disease activity in patients with clinically isolated syndrome and early relapsing-remitting MS without causing serious adverse events, according to a 2026 review in Expert Opinion on Pharmacotherapy.
Vitamin D deficiency is established as a risk factor for multiple sclerosis development, and emerging evidence suggests supplementation may be more beneficial when started at the clinically isolated syndrome stage rather than after MS is fully diagnosed.
Researchers note that vitamin D’s mechanism of action differs from established MS medications like interferon beta and teriflunomide, suggesting potential additive benefits when vitamin D supplementation is combined with these treatments.
The Quick Take
- What they studied: Whether giving vitamin D3 supplements to people showing early signs of multiple sclerosis could slow down or prevent the disease from developing further.
- Who participated: People with clinically isolated syndrome (CIS)—a condition where patients experience symptoms that could lead to MS—and those in early stages of relapsing-remitting MS. The exact number of participants wasn’t specified in the available information.
- Key finding: The D-Lay MS clinical trial showed that vitamin D3 supplements reduced disease activity in people with CIS and early-stage MS, and the treatment was safe with no serious side effects reported.
- What it means for you: If you’ve been diagnosed with CIS or early MS, vitamin D supplementation might be worth discussing with your doctor as an additional treatment option, especially since it appears safe. However, this should complement—not replace—proven MS treatments like interferon beta or teriflunomide.
The Research Details
This research article reviews evidence from the D-Lay MS clinical trial, which tested whether vitamin D3 supplements could help people in the earliest stages of multiple sclerosis. The trial examined patients with clinically isolated syndrome (CIS)—a condition where people experience their first MS-like symptoms but haven’t yet been diagnosed with full MS—as well as those with early relapsing-remitting MS, the most common form of the disease.
The researchers gave some patients vitamin D3 supplements while monitoring their disease activity over time. They tracked whether the supplements reduced the number of new brain lesions and other signs that MS was progressing. The study also carefully watched for any harmful side effects from the vitamin D treatment.
This approach is important because it tests vitamin D at the earliest possible stage of disease—before MS fully develops—when intervention might have the strongest protective effect. The researchers also considered how vitamin D might work alongside other established MS medications.
Testing vitamin D in CIS is important because it’s the earliest point where doctors can intervene. If vitamin D can slow or prevent progression from CIS to full MS, it could change how doctors treat patients at this critical stage. Additionally, vitamin D is inexpensive, widely available, and appears to have minimal side effects, making it a potentially practical addition to existing treatments.
The research is based on a clinical trial (D-Lay MS), which is a stronger type of evidence than observational studies. However, the specific sample size and demographic details (including race and ethnicity of participants) were not provided in this review, which limits our ability to fully assess the study’s scope and generalizability. The authors themselves note that future studies should include more detailed demographic information. The fact that no serious adverse events were reported is a positive quality indicator for safety.
What the Results Show
The D-Lay MS clinical trial demonstrated that vitamin D3 supplementation reduced disease activity in people with clinically isolated syndrome and those in early stages of relapsing-remitting MS. This means that patients taking vitamin D3 showed fewer signs of their disease progressing, such as fewer new brain lesions on MRI scans. The reduction in disease activity is significant because it suggests vitamin D may help slow the disease’s progression during this critical early window.
Importantly, the vitamin D supplementation was well-tolerated, with no serious adverse events reported. This safety profile is encouraging because it means patients could potentially take vitamin D supplements without worrying about major side effects. The lack of serious harm makes vitamin D an attractive option to consider alongside other MS treatments.
The researchers noted that vitamin D’s mechanism of action—how it works in the body—is different from other established MS medications like interferon beta and teriflunomide. This difference suggests that vitamin D and these other drugs might work together synergistically, potentially offering additive benefits when used in combination.
The research highlights that vitamin D deficiency is a known risk factor for developing MS in the first place. This suggests that maintaining adequate vitamin D levels might be protective at multiple stages of the disease. The authors also emphasize the need for long-term follow-up studies to understand how vitamin D supplementation started in the CIS stage affects disease progression over years, not just months.
While vitamin D deficiency has long been recognized as a risk factor for MS, previous research showed that vitamin D supplementation has only limited benefit in people who already have established MS. This new research suggests that vitamin D may be more effective when given earlier—in the CIS stage before MS fully develops. This represents a shift in thinking about when vitamin D intervention might be most helpful. The combination approach with other medications also differs from previous research that looked at vitamin D alone.
The study has several important limitations. First, the specific number of participants in the D-Lay MS trial was not provided, making it difficult to assess how robust the findings are. Second, the demographic information about participants—including their race and ethnicity—was not included, which is important for understanding whether these results apply equally to all populations. The authors specifically call for future studies to include this information. Third, this review doesn’t provide details about the long-term effects of vitamin D supplementation or how long patients were followed. Finally, while the results are promising, larger and longer studies are needed to confirm these findings and establish optimal dosing.
The Bottom Line
Based on current evidence, vitamin D supplementation may be worth considering as part of a comprehensive treatment plan for people with clinically isolated syndrome or early MS, in consultation with their neurologist. The confidence level is moderate—the evidence is promising but not yet definitive. Vitamin D should complement, not replace, proven MS medications like interferon beta or teriflunomide. People interested in vitamin D supplementation should discuss appropriate dosing with their healthcare provider.
This research is most relevant to people who have been diagnosed with clinically isolated syndrome (CIS) or are in the early stages of relapsing-remitting MS. It may also interest people with a family history of MS or those with vitamin D deficiency who want to reduce their MS risk. Healthcare providers treating MS patients should be aware of this emerging evidence. People with established, advanced MS may see less benefit based on previous research, though discussion with their doctor is warranted.
The D-Lay MS trial showed reduced disease activity, but the timeframe for these improvements wasn’t specified in this review. Typically, changes in MS disease activity can be detected within months on MRI scans, but physical improvements may take longer. Long-term benefits and effects on progression to full MS would require years of follow-up to fully understand.
Frequently Asked Questions
Can vitamin D supplements prevent multiple sclerosis from developing?
The D-Lay MS trial showed vitamin D3 reduced disease activity in early MS stages, but it’s not yet proven to prevent MS entirely. Vitamin D appears most helpful when started early in clinically isolated syndrome, before full MS develops. More research is needed to confirm prevention effects.
Is vitamin D safe to take if I have MS or CIS?
Yes, according to the D-Lay MS clinical trial, vitamin D3 supplementation was well-tolerated with no serious adverse events reported in people with CIS and early MS. However, discuss appropriate dosing with your neurologist, as individual needs vary.
Should I take vitamin D instead of my MS medications?
No. Vitamin D should complement established MS treatments like interferon beta or teriflunomide, not replace them. The different mechanisms of action suggest these treatments may work better together. Always consult your doctor before changing your treatment plan.
How long does it take to see benefits from vitamin D supplementation in MS?
The D-Lay MS trial showed reduced disease activity, but specific timeframes weren’t detailed in this review. Disease activity changes can appear on MRI scans within months, but physical improvements may take longer. Long-term effects require years of follow-up to fully understand.
Who should consider vitamin D supplementation for MS prevention?
People diagnosed with clinically isolated syndrome or early relapsing-remitting MS are the primary candidates based on current evidence. Those with vitamin D deficiency or family history of MS may also benefit from discussion with their healthcare provider about supplementation.
Want to Apply This Research?
- Track daily vitamin D supplementation intake (dosage and time) alongside monthly symptom severity ratings and any new neurological symptoms. Users can log vitamin D doses and rate energy levels, cognitive clarity, and relapse frequency on a 1-10 scale to identify patterns.
- Users with CIS or early MS can set a daily reminder to take their vitamin D supplement at the same time each day, paired with a meal for better absorption. The app can send weekly summaries showing consistency and correlate supplementation adherence with symptom tracking data.
- Establish a baseline of disease activity markers (if available from medical records) and track them quarterly. Monitor for any new symptoms or changes in existing symptoms monthly. Share tracked data with healthcare providers during regular appointments to inform treatment decisions and assess whether vitamin D supplementation is contributing to disease stability.
This article summarizes research findings and should not be considered medical advice. Vitamin D supplementation decisions should be made in consultation with your neurologist or healthcare provider, particularly if you have clinically isolated syndrome, multiple sclerosis, or are taking other medications. The D-Lay MS trial results are promising but represent emerging evidence; larger and longer studies are needed to confirm findings. Do not start, stop, or change any MS medications or supplements without professional medical guidance. This information is current as of April 2026 and may be updated as new research emerges.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.